Drug intelligence / Profile preview

Program 3 (Tasca Therapeutics)

Development stage: Preclinical
Lead developer: Tasca Therapeutics

Overview

Program 3 is a discovery-stage drug development program being conducted by Tasca Therapeutics, a biotechnology company specializing in small molecule inhibitors of protein palmitoylation. While the company's lead candidate, CP-383, targets auto-palmitoylated proteins, the specific molecular target and therapeutic modality for Program 3 have not yet been publicly disclosed. The program is currently being evaluated for various cancer indications and represents an early-stage research asset within the company's oncology pipeline.

Beyond the preview

Go deeper on Program 3 (Tasca Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Program 3 (Tasca Therapeutics).

Explore the full profile